Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 registration study of Sotigalimab in combination with doxorubicin as a treatment of patients with anthracycline-naive, advanced LPS.

Next Previous
Trial Profile

A Phase 3 registration study of Sotigalimab in combination with doxorubicin as a treatment of patients with anthracycline-naive, advanced LPS.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Sotigalimab (Primary)
  • Indications Liposarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Apexigen; Pyxis Oncology

Most Recent Events

  • 23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology.
  • 25 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top